Patients with chronic hepatitis B were stratified into two groups: patients with inactive chronic hepatitis B (carriers, n = 30), and those with active chronic hepatitis B who were under treatment with PEG-IFN-α-2a (n = 20) for minimum six and maximum 12 months. This evidence concerns the gene IFNA2 and chronic hepatitis B virus infection.